Abstract: The invention involves a novel method of converting atrial fibrillation (AF) or atrial flutter (AFL) in a patient presenting with highly symptomatic AF or AFL by administering at least a loading dose of dofetilide intravenously, or if that fails cardioversion and a maintenance infusion followed by a switch to chronic oral dosing.

Abstract: The present invention involves novel safe dosage regimens comprising the administration of a loading and maintenance dose of dofetilide iv, followed by oral dosing of dofetilide. Methods include (a) reducing the risk of developing atrial fibrillation (AF) and/or atrial flutter (AFL) post coronary bypass surgery (CABS); (b) terminating arrhythmic storm in patients following implementation of an implantable defibrillator by administrating loading and maintenance infusions of dofetilide intravenously followed by oral dosing; and, (c) converting atrial fibrillation (AF) or atrial flutter (AFL) in a patient presenting with highly symptomatic AF or AFL.

Abstract: The present invention provides novel methods of administering sotalol hydrochloride to patients in need thereof.

Abstract: The present invention involves a novel method of reducing the risk of developing atrial fibrillation (AF) and/or atrial flutter (AFL) post coronary bypass surgery (CABS) by administering, to patients who have undergone CABS, loading and maintenance doses of dofetilide intravenously followed by oral doses.

Abstract: Some aspects provide novel dofetilide derivatives and pharmaceutical compositions containing the same that are useful as pharmaceutical agents in the treatment of supraventricular and ventricular arrhythmias.

Abstract: The present invention provides a novel method of initiating or escalating dofetliide dosage with the goal of maximizing patient safety while shortening the time period required for electrocardiogramonitoring from three days to one day.

Abstract: The invention involves a novel method of converting atrial fibrillation (AF) or atrial flutter (AFL) in a patient presenting with highly symptomatic AF or AFL by administering at least a loading dose of dofetilide intravenously, or if that fails cardioversion and a maintenance infusion followed by a switch to chronic oral dosing.

Abstract: The invention involves a novel method of terminating arrhythmic storm in patients following implementation of an implantable defibrillator by administrating loading and maintenance infusions of dofetilide intravenously followed by oral dosing.

Abstract: The present invention involves a novel method of reducing the risk of developing atrial fibrillation (AF) and/or atrial flutter (AFL) post coronary bypass surgery (CABS) by administering, to patients who have undergone CABS, loading and maintenance doses of dofetilide intravenously followed by oral doses.

Abstract: The present invention provides novel methods of initiating and escalating sotalol hydrochloride in patients in need thereof.

Abstract: The present invention provides a novel method of initiating or escalating dofetilide dosage with the goal of maximizing patient safety while shortening the time period required for electrocardiographic monitoring from three days to one day.

Abstract: Some aspects provide novel dofetilide derivatives and pharmaceutical compositions containing the same that are useful as pharmaceutical agents in the treatment of supraventricular and ventricular arrhythmias.

Abstract: Some aspects provide novel dofetilide derivatives and pharmaceutical compositions containing the same that are useful as pharmaceutical agents in the treatment of supraventricular and ventricular arrhythmias.

Abstract: This disclosure provides a method of safely and rapidly initiating or escalating oral sotalol therapy by administering an intravenous dosage of sotalol followed by oral sotalol twice daily.

Abstract: The present invention provides novel methods of administering sotalol hydrochloride to patients in need thereof.

Abstract: Some aspects provide novel dofetilide derivatives and pharmaceutical compositions containing the same that are useful as pharmaceutical agents in the treatment of supraventricular and ventricular arrhythmias.

Abstract: The present invention provides a novel method of initiating or escalating dofetliide dosage with the goal of maximizing patient safety while shortening the time period required for electrocardiographic monitoring from three days to one day.

Abstract: The present invention provides a novel method of converting AF and monitoring normal sinus rhythm using an initial IV dose of sotalol followed by oral sotalol maintenance therapy. This method provides a method of acute assessment of QTc prolongation to determine the safety of chronic oral sotalol therapy and reduces the hospitalization stay required for conversion and sotalol initiation.

Abstract: The present invention provides novel methods of initiating and escalating sotalol hydrochloride in patients in need thereof.

Abstract: The present invention provides novel sotalol derivatives and pharmaceutical compositions containing the same that are are useful as pharmaceutical agents in the treatment of supraventricular and ventricular arrhythmias.